PDSB (STOCKS)
PDS Biotechnology Corporation Common Stock
$1.080000
+0.000000 (+0.00%)
Prev close: $1.080000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Frank K. Bedu-Addo
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $61.12M
- Employees
- 24
- P/E (TTM)
- -1.46
- P/B (TTM)
- 6.41
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.15 | $-0.19 | +0.0472 | +24.36% |
|
Sep 2025 (Q3)
|
$-0.19 | $-0.22 | +0.0276 | +12.68% |
|
Jun 2025 (Q2)
|
$-0.21 | $-0.24 | +0.0280 | +11.76% |
|
Mar 2025 (Q1)
|
$-0.21 | $-0.25 | +0.0416 | +16.53% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $31.54M |
| Research and Development | $19.03M |
| Other Operating Expenses | $12.52M |
| Operating Income/Loss | -$31.54M |
| Income/Loss From Continuing Operations After Tax | -$34.50M |
| Income/Loss From Continuing Operations Before Tax | -$35.67M |
| Income Tax Expense/Benefit | -$1.17M |
| Income Tax Expense/Benefit, Current | -$1.17M |
| Net Income/Loss | -$34.50M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$34.50M |
| Net Income/Loss Available To Common Stockholders, Basic | -$34.50M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.74 |
| Diluted Earnings Per Share | -$0.74 |
| Basic Average Shares | 46,384,280 |
| Diluted Average Shares | 46,384,280 |
| Assets | $30.49M |
| Current Assets | $28.25M |
| Noncurrent Assets | $2.24M |
| Fixed Assets | $120.18K |
| Other Non-current Assets | $2.12M |
| Liabilities | $21.24M |
| Current Liabilities | $9.48M |
| Accounts Payable | $3.57M |
| Other Current Liabilities | $5.91M |
| Noncurrent Liabilities | $11.76M |
| Equity | $9.25M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $9.25M |
| Liabilities And Equity | $30.49M |
| Net Cash Flow From Operating Activities | -$27.75M |
| Net Cash Flow From Operating Activities, Continuing | -$27.75M |
| Net Cash Flow From Investing Activities | $14.98M |
| Net Cash Flow From Investing Activities, Continuing | $14.98M |
| Net Cash Flow From Financing Activities | $12.77M |
| Net Cash Flow From Financing Activities, Continuing | $12.77M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$34.50M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$34.50M |
| Other Comprehensive Income/Loss | -$34.50M |